Scenarios 2027 / Scenarios
Rated at Standard Severe. Likelihood type: systemic. Source of scores: ginc-desk-v0.3. Upside scenario: impact levels measure the scale of change, not loss.
The health ministry's annual report has a chart nobody has seen before: admissions for heart attack and stroke down for the third year, by a fifth in all. The obesity drug that cost a month's wages in 2024 is a generic tablet bought with the groceries. The HIV clinic in the township gives two injections a year and has recorded no new infection among its regular patients since it opened. In the villages to the north, the children's ward that filled every rainy season has empty beds; the malaria vaccine is given with the measles one. A cancer vaccine is made to order for each patient in six weeks, and the first drug designed end to end by a model has been on pharmacy shelves for a year. The actuaries noticed before the politicians. Life expectancy at 65 is up two years in five, the pension fund's deficit has doubled and the retirement age is back in parliament. A dialysis chain files for protection. Sugar and snack makers issue profit warnings. The harder story is next door, where the same medicines are licensed but the cold chain, the nurses and the budget are not there. Its government is asked why its citizens die of what the neighbours no longer catch.
The dateline is illustrative, not a forecast. The narrative is hypothetical; the historical anchors below are real events.
Several medical advances reach scale in the same five years: cheap generic obesity and diabetes drugs, long-acting HIV prevention, effective malaria vaccines, personalised cancer vaccines and the first medicines designed by AI. Together they cut the burden of the main killers by a fifth in countries that deploy them and add years of healthy life. Health systems shift from treatment to prevention. The gains depend on price, manufacturing and delivery, so they arrive first where systems already work. Longer lives strain pensions and care, and industries built on chronic disease shrink.
A shock most would count as progress. It is not upside for everyone: each record names who gains and who loses. Impact levels measure the scale of change, in either direction, and loads mark the capabilities a nation needs in order to capture the gain or absorb the loss.
| Event | Date | What happened | Calibrates |
|---|---|---|---|
| Combination antiretroviral therapy | 1996 onward | Turned HIV from a fatal to a chronic condition; access in Africa lagged by about a decade | speed of benefit; the access gap |
| COVID-19 mRNA vaccines | 2020 | Vaccines were authorised within about 11 months of the pathogen being sequenced | speed of development at scale |
| GLP-1 medicines | 2021–2026 | Demand outran supply for years; generic semaglutide launched in India in March 2026 and was approved in Canada | price as the gate to scale |
| Lenacapavir for HIV prevention | 2024–2026 | A twice-yearly injection; more than 55,000 people had started it in South Africa's public system by September 2026 | delivery in a high-burden setting |
| Malaria vaccines RTS,S and R21 | 2021–2024 | WHO recommended RTS,S in 2021 and R21 in 2023; routine childhood use began in African countries in 2024 | low-cost prevention at scale |
| AI-designed drug candidates | July 2026 | No AI-designed drug had full approval; the most advanced candidate entered a Phase III trial | counter-anchor on speed |
| Smallpox eradication | 1980 | Declared eradicated after a global vaccination campaign | Standard Extreme precedent |
Shown at their preset values. Parameters are not adjustable in this release and nothing on this page is computed from them. Custom settings run (Phase B) but are labelled 'non-standard run' and excluded from comparisons.
| Parameter | Default | Range or options | Note |
|---|---|---|---|
| Fall in burden of the leading causes of death where deployed | 20 per cent | 10–40 | — |
| Gain in healthy life expectancy | 2 years | 1–5 | — |
| Price relative to launch price | one tenth | one half to one hundredth | — |
| Lag between high-income and low-income access | 5 years | 1–15 | — |
| Technologies in the wave | 5 | 3–8 | — |
| Readiness of delivery systems | uneven | options: ready / absent | — |
High: capability band shifts expected under current plans. Medium: band shifts under 'none' policy response only. Low: strain without band shift. Loads are judgement-based until the Atlas connects. Domains link to the Atlas.
| Domain | Load | Channel |
|---|---|---|
| Hard | ||
| Defence and security | Low | fitter recruits; biosecurity of new platforms |
| Strategic infrastructure | Medium | cold chain, primary care and manufacturing sites |
| Critical technology | High | drug discovery, biomanufacturing and regulatory science |
| Soft | ||
| Government effectiveness | High | procurement, pricing, regulation and delivery at scale |
| Human capital | High | healthy life years, workforce participation, child survival |
| Influence and cohesion | Medium | access inequality; health diplomacy |
| Economic | ||
| Macro-financial | High | pension liabilities, health budgets, labour supply |
| Industry, trade and supply | Medium | pharmaceutical trade; decline of chronic-care industries |
| Energy and resources | Low | food demand shifts |
| Region | Exposure | Rationale |
|---|---|---|
| North America | High | High obesity and drug prices; large gains once prices fall |
| Europe | High | Ageing populations gain health and face pension strain |
| China | High | Rapid ageing and large domestic manufacturing |
| Indo-Pacific | High | Japan and Korea face the sharpest longevity pressure |
| South Asia | High | Generic manufacturing base; large diabetes burden |
| Gulf and Middle East | Medium | High diabetes prevalence; capacity to pay |
| Africa | High | Largest gains from HIV and malaria prevention; delivery is the constraint |
| Latin America and Caribbean | Medium | Rising chronic disease; uneven systems |
| Russia and Eurasia | Medium | High cardiovascular mortality; access constrained |
| Indicator | Source | Threshold |
|---|---|---|
| Price and generic availability of GLP-1 medicines by country | — | — |
| People on long-acting HIV prevention | UNAIDS, national programmes | — |
| Malaria vaccine coverage and child mortality | WHO, Gavi | — |
| Approvals of AI-designed medicines | FDA, EMA | — |
| Cardiovascular admissions and mortality rates | — | — |
| Life expectancy at 65 and pension funding ratios | — | — |
| Late-stage cancer vaccine trial results | — | — |
From the GINC 250: trends rated Very high or Critical for this scenario. All S17 trend scores.
| Rating | Band or level | Why |
|---|---|---|
| Likelihood, two years | 3Possible | Three of the pieces are in rollout: generic semaglutide launched in India and Canada in 2026, twice-yearly lenacapavir reached more than 55,000 people in South Africa within months, and two malaria vaccines are in routine use. No AI-designed drug has yet been approved. |
| Likelihood, ten years | 4Likely | Pipelines in obesity, HIV, malaria and cancer vaccines mature within the decade. |
| Systemic impact | 3Significant | Level 3 as a gain: a healthier workforce and a lower disease burden, offset by pension and care costs. |
| National impact | 4Major | Level 4: high-burden nations gain years of healthy life; ageing nations face a pension and fiscal reset. |
| Confidence | low | Uptake, price and durability of effect are all uncertain. |
Source of scores: ginc-desk-v0.3. Confidence refers to the rating, not the scenario. Calibration sources are listed with the anchors above and on the methodology page.
Contested assumptions for the panel to resolve.
No signed commentary in this build.
0.3.0 · active0.3.0 · 3 October 2026 · Entered the Library at v0.3 as an upside scenario, with GINC desk scores.GINC (2027). Scenario S17 Biomedical breakthrough wave, Scenario Library v0.3. scenarios.ginc.org/library/biomedical-breakthrough-waveContent and data are published under CC BY 4.0.